Phase 1/2, Open-Label, Randomized Study Of The Safety, Efficacy, And Pharmacokinetics Of Erlotinib With Or Without PF-02341066 In Patients With Advanced Non-Small Cell Adenocarcinoma Of The Lung.

Trial Profile

Phase 1/2, Open-Label, Randomized Study Of The Safety, Efficacy, And Pharmacokinetics Of Erlotinib With Or Without PF-02341066 In Patients With Advanced Non-Small Cell Adenocarcinoma Of The Lung.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs Crizotinib (Primary) ; Erlotinib
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Sep 2016 Results published in the Journal of Thoracic Oncology.
    • 06 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top